cimetidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
histamine-H2-receptor antagonists, cimetidine derivatives	645	51481-61-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cimetidine tagamet tametin ulcedin ulcedine ulcerex ulcerfen cimetidine hydrochloride cimetidine HCl	A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output. Molecular weight: 252.34 Formula: C10H16N6S CLOGP: 0.38 LIPINSKI: 0 HAC: 6 HDO: 3 TPSA: 88.89 ALOGS: -3.16 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cimetidine
tagamet
tametin
ulcedin
ulcedine
ulcerex
ulcerfen
cimetidine hydrochloride
cimetidine HCl

A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.

Molecular weight: 252.34
Formula: C10H16N6S
CLOGP: 0.38
LIPINSKI: 0
HAC: 6
HDO: 3
TPSA: 88.89
ALOGS: -3.16
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.80	g	O
0.80	g	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	6.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	62 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	158.51 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	60 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.20 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	8.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.78 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	2.20 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 16, 1977	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	141.13	13.18	56	13833	6182	50585053
Urine leukocyte esterase positive	121.71	13.18	41	13848	2842	50588393
Body tinea	111.63	13.18	32	13857	1295	50589940
Inhibitory drug interaction	95.22	13.18	32	13857	2201	50589034
Infection susceptibility increased	90.64	13.18	32	13857	2552	50588683
Lymphocyte count decreased	80.81	13.18	63	13826	26244	50564991
Glucose tolerance impaired	72.61	13.18	33	13856	5085	50586150
Impaired quality of life	67.32	13.18	33	13856	6023	50585212
Culture urine positive	64.43	13.18	27	13862	3424	50587811
Urine ketone body present	63.63	13.18	24	13865	2309	50588926
Purpura	57.17	13.18	35	13854	9876	50581359
Chronic kidney disease	56.70	13.18	62	13827	39709	50551526
Hyperlipidaemia	56.13	13.18	43	13846	17447	50573788
Blood urine present	55.95	13.18	38	13851	12795	50578440
Poor quality sleep	51.40	13.18	40	13849	16606	50574629
Bone density decreased	51.17	13.18	34	13855	11041	50580194
Anaphylactoid reaction	48.44	13.18	22	13867	3384	50587851
Drug intolerance	48.26	13.18	3	13886	219101	50372134
Erythema	43.17	13.18	112	13777	146302	50444933
Impaired work ability	40.43	13.18	32	13857	13608	50577627
Neutrophil count increased	37.22	13.18	31	13858	14164	50577071
Joint swelling	36.51	13.18	11	13878	245275	50345960
Torsade de pointes	35.59	13.18	28	13861	11807	50579428
Oral herpes	34.31	13.18	35	13854	20690	50570545
Rheumatoid arthritis	34.17	13.18	7	13882	202543	50388692
Skin disorder	31.73	13.18	36	13853	23994	50567241
Hypertension	31.54	13.18	128	13761	211075	50380160
Drug ineffective	31.20	13.18	118	13771	819215	49772020
Bacterial test positive	30.66	13.18	18	13871	4705	50586530
Band sensation	29.86	13.18	10	13879	680	50590555
Keratitis	28.99	13.18	14	13875	2471	50588764
Tri-iodothyronine free decreased	28.44	13.18	8	13881	302	50590933
Creatinine urine decreased	27.92	13.18	7	13882	168	50591067
Infusion site scar	27.80	13.18	8	13881	328	50590907
Red cell distribution width increased	27.36	13.18	21	13868	8538	50582697
Specific gravity urine decreased	25.98	13.18	9	13880	678	50590557
Urticaria	25.60	13.18	86	13803	129475	50461760
Cataract	23.96	13.18	45	13844	47255	50543980
Infusion site discomfort	23.83	13.18	9	13880	869	50590366
Anxiety	23.67	13.18	104	13785	177502	50413733
Product use issue	23.53	13.18	6	13883	149469	50441766
Electrocardiogram T wave amplitude decreased	23.20	13.18	7	13882	339	50590896
Insomnia	23.00	13.18	102	13787	174763	50416472
Product dose omission issue	22.76	13.18	11	13878	183827	50407408
Cellulitis	22.75	13.18	56	13833	70742	50520493
Circulatory collapse	21.52	13.18	27	13862	19973	50571262
Red blood cell count decreased	20.75	13.18	35	13854	33800	50557435
Basophil count increased	20.68	13.18	8	13881	824	50590411
Alanine aminotransferase increased	20.50	13.18	62	13827	88297	50502938
Therapeutic product effect decreased	20.41	13.18	6	13883	136044	50455191
Death	19.93	13.18	155	13734	325224	50266011
Blood thyroid stimulating hormone increased	19.59	13.18	15	13874	6077	50585158
Peripheral swelling	19.15	13.18	17	13872	205919	50385316
Red blood cells urine positive	19.14	13.18	11	13878	2764	50588471
Protein urine present	18.98	13.18	14	13875	5363	50585872
Food interaction	18.81	13.18	7	13882	649	50590586
Arthropathy	18.71	13.18	10	13879	157896	50433339
Palmar-plantar erythrodysaesthesia syndrome	18.31	13.18	25	13864	20073	50571162
Contraindicated product administered	18.30	13.18	9	13880	148949	50442286
Chromaturia	17.82	13.18	21	13868	14569	50576666
White blood cell count decreased	17.60	13.18	71	13818	116651	50474584
C-reactive protein abnormal	17.36	13.18	29	13860	27780	50563455
Wound	17.13	13.18	4	13885	105790	50485445
Infusion site rash	17.00	13.18	8	13881	1334	50589901
Urobilinogen urine increased	16.76	13.18	5	13884	233	50591002
Systemic lupus erythematosus	16.52	13.18	9	13880	140613	50450622
Infusion site warmth	16.49	13.18	8	13881	1426	50589809
Flushing	16.47	13.18	48	13841	66967	50524268
Nitrite urine present	16.46	13.18	7	13882	920	50590315
Pancreatitis acute	16.45	13.18	26	13863	23786	50567449
Maternal exposure during pregnancy	16.34	13.18	12	13877	159766	50431469
Thyroid cyst	16.01	13.18	6	13883	567	50590668
Feeling hot	15.90	13.18	34	13855	39168	50552067
Red cell distribution width decreased	15.28	13.18	7	13882	1098	50590137
Glucose urine present	14.93	13.18	6	13883	684	50590551
Drug exposure before pregnancy	14.61	13.18	6	13883	723	50590512
Immune thrombocytopenia	14.51	13.18	15	13874	9002	50582233
Monocyte count decreased	14.42	13.18	8	13881	1878	50589357
pH urine increased	14.35	13.18	5	13884	383	50590852
Abdominal discomfort	13.50	13.18	27	13862	231614	50359621
Ventricular tachycardia	13.40	13.18	19	13870	15802	50575433

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Chronic kidney disease	33.78	16.02	38	5572	36378	29532539
Renal injury	19.75	16.02	16	5594	10186	29558731
Palmar-plantar erythrodysaesthesia syndrome	18.32	16.02	18	5592	14741	29554176
Peptic ulcer	18.02	16.02	9	5601	2476	29566441

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urine abnormality	150.32	13.17	60	16255	7302	64475115
Urine leukocyte esterase positive	118.31	13.17	41	16274	3362	64479055
Body tinea	110.46	13.17	31	16284	1262	64481155
Lymphocyte count decreased	88.37	13.17	77	16238	40622	64441795
Infection susceptibility increased	87.70	13.17	31	16284	2695	64479722
Inhibitory drug interaction	86.18	13.17	33	16282	3594	64478823
Urine ketone body present	71.16	13.17	28	16287	3279	64479138
Glucose tolerance impaired	64.93	13.17	32	16283	6411	64476006
Impaired quality of life	64.80	13.17	32	16283	6439	64475978
Culture urine positive	61.74	13.17	27	16288	4124	64478293
Bone density decreased	54.47	13.17	33	16282	9919	64472498
Poor quality sleep	51.83	13.17	41	16274	18910	64463507
Hyperlipidaemia	50.93	13.17	44	16271	22932	64459485
Blood urine present	46.59	13.17	38	16277	18302	64464115
Purpura	46.50	13.17	37	16278	17209	64465208
Erythema	44.91	13.17	126	16189	186944	64295473
Anaphylactoid reaction	43.23	13.17	22	16293	4716	64477701
Hypertension	41.58	13.17	152	16163	259109	64223308
Torsade de pointes	35.97	13.17	32	16283	17331	64465086
Impaired work ability	35.47	13.17	30	16285	15189	64467228
Red cell distribution width increased	34.45	13.17	27	16288	12282	64470135
Oral herpes	32.93	13.17	34	16281	22118	64460299
Urticaria	31.27	13.17	95	16220	147222	64335195
Palmar-plantar erythrodysaesthesia syndrome	30.42	13.17	37	16278	28782	64453635
Infusion site scar	30.33	13.17	8	16307	257	64482160
Keratitis	29.44	13.17	15	16300	3222	64479195
Skin disorder	28.35	13.17	35	16280	27645	64454772
Tri-iodothyronine free decreased	27.88	13.17	8	16307	353	64482064
Chronic kidney disease	27.31	13.17	51	16264	57868	64424549
Flushing	27.29	13.17	61	16254	78587	64403830
Red blood cell count decreased	27.18	13.17	46	16269	48340	64434077
Band sensation	26.94	13.17	9	16306	660	64481757
Bacterial test positive	26.26	13.17	18	16297	6672	64475745
Alanine aminotransferase increased	26.15	13.17	86	16229	138945	64343472
Joint swelling	25.94	13.17	11	16304	215371	64267046
Infusion site discomfort	25.74	13.17	9	16306	757	64481660
Specific gravity urine decreased	25.55	13.17	9	16306	774	64481643
Off label use	25.49	13.17	79	16236	632727	63849690
Insomnia	25.23	13.17	108	16207	197728	64284689
Cataract	22.76	13.17	44	16271	51218	64431199
Monocyte count decreased	22.44	13.17	12	16303	2845	64479572
Peptic ulcer	22.41	13.17	15	16300	5348	64477069
Creatinine urine decreased	21.98	13.17	6	16309	220	64482197
Secondary adrenocortical insufficiency	21.72	13.17	11	16304	2334	64480083
Drug ineffective	21.43	13.17	125	16190	840122	63642295
Ventricular tachycardia	21.16	13.17	34	16281	34231	64448186
Basophil count increased	21.12	13.17	9	16306	1291	64481126
Contusion	20.98	13.17	70	16245	113895	64368522
Neutrophil count increased	19.85	13.17	28	16287	25146	64457271
Infusion site warmth	19.35	13.17	8	16307	1064	64481353
White blood cell count decreased	19.22	13.17	85	16230	157752	64324665
Red cell distribution width decreased	19.20	13.17	8	16307	1085	64481332
Dyspepsia	19.14	13.17	54	16261	80258	64402159
Infusion site rash	19.11	13.17	8	16307	1098	64481319
Rheumatoid arthritis	18.82	13.17	9	16306	164285	64318132
Mean cell haemoglobin increased	18.51	13.17	11	16304	3191	64479226
Haematocrit increased	18.06	13.17	11	16304	3334	64479083
Blood thyroid stimulating hormone increased	17.65	13.17	15	16300	7639	64474778
Protein urine present	17.55	13.17	16	16299	8940	64473477
Anxiety	17.49	13.17	99	16216	202550	64279867
Drug exposure before pregnancy	17.34	13.17	6	16309	489	64481928
Therapeutic product effect decreased	17.25	13.17	4	16311	115347	64367070
Gastrooesophageal reflux disease	17.05	13.17	53	16262	83090	64399327
Therapeutic product effect incomplete	16.69	13.17	3	16312	103479	64378938
Leukocyturia	16.58	13.17	8	16307	1530	64480887
Electrocardiogram T wave amplitude decreased	16.57	13.17	6	16309	559	64481858
Nitrite urine present	16.03	13.17	7	16308	1065	64481352
Peripheral swelling	15.54	13.17	18	16297	209135	64273282
C-reactive protein abnormal	15.50	13.17	27	16288	29020	64453397
Product dose omission issue	15.30	13.17	16	16299	194731	64287686
Infusion site pruritus	15.19	13.17	9	16306	2597	64479820
Eosinophil count increased	14.70	13.17	18	16297	14094	64468323
Thyroid cyst	14.69	13.17	5	16310	388	64482029
Blood alkaline phosphatase increased	14.56	13.17	39	16276	56240	64426177
pH urine increased	14.20	13.17	5	16310	429	64481988
Aspartate aminotransferase increased	14.19	13.17	64	16251	119724	64362693
Food interaction	13.94	13.17	7	16308	1459	64480958
Duodenal ulcer haemorrhage	13.78	13.17	12	16303	6313	64476104
Cellulitis	13.39	13.17	53	16262	93604	64388813
Product use in unapproved indication	13.33	13.17	15	16300	176603	64305814
White blood cells urine positive	13.32	13.17	11	16304	5387	64477030

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BA01	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
ATC	A02BA51	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists
FDA MoA	N0000000151	Histamine H2 Receptor Antagonists
CHEBI has role	CHEBI:37961	H2 receptor antagonists
CHEBI has role	CHEBI:49201	anti-ulcer drugs
CHEBI has role	CHEBI:50183	P450 inhibitors
CHEBI has role	CHEBI:60809	adjuvants
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D065609	Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA	D065607	Cytochrome P-450 Enzyme Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D006633	Histamine Antagonists
MeSH PA	D006635	Histamine H2 Antagonists
MeSH PA	D065606	Metabolic Side Effects of Drugs and Substances
MeSH PA	D018377	Neurotransmitter Agents
FDA EPC	N0000175784	Histamine-2 Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Heartburn	indication	16331000
Upper gastrointestinal hemorrhage	indication	37372002
Duodenal ulcer disease	indication	51868009	DOID:1724
Zollinger-Ellison syndrome	indication	53132006	DOID:0050782
Multiple endocrine adenomas	indication	60549007
Indigestion	indication	162031009
Gastroesophageal reflux disease	indication	235595009	DOID:8534
Systemic mast cell disease	indication	397016004	DOID:349
Gastric ulcer	indication	397825006	DOID:10808
Upper GI Bleed Prevention	indication
Maintenance of Healing Duodenal Ulcer	indication
Pancreatic insufficiency	off-label use	37992001
Urticaria	off-label use	126485001
Prevention of Stress Ulcer	off-label use
NSAID-Induced Gastric Ulcer	off-label use
Impaired renal function disorder	contraindication	197663003
Disease of liver	contraindication	235856003	DOID:409
Malignant tumor of stomach	contraindication	363349007	DOID:10534

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.83	acidic
pKa2	6.71	Basic
pKa3	0.0	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Histamine H2 receptor	GPCR	P25021	HRH2_HUMAN	ANTAGONIST	Kd	6.14	WOMBAT-PK	CHEMBL
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN		Ki	5.16	PDSP
Multidrug and toxin extrusion protein 1	Transporter	Q96FL8	S47A1_HUMAN		IC50	5.92	CHEMBL
Multidrug and toxin extrusion protein 2	Transporter	Q86VL8	S47A2_HUMAN	INHIBITOR	Ki	5.10	IUPHAR
Histamine H2 receptor	GPCR		HRH2_CAVPO		Kd	6.58	CHEMBL
Histamine H2 receptor	GPCR		HRH2_RAT	ANTAGONIST	Ki	5.90	IUPHAR

External reference:

ID	Source
4018845	VUID
N0000147147	NUI
D00295	KEGG_DRUG
70059-30-2	SECONDARY_CAS_RN
152402	RXNORM
4018844	VANDF
4018845	VANDF
C0008783	UMLSCUI
CHEBI:3699	CHEBI
CHEMBL30	ChEMBL_ID
CHEMBL1201051	ChEMBL_ID
DB00501	DRUGBANK_ID
D002927	MESH_DESCRIPTOR_UI
2756	PUBCHEM_CID
1231	IUPHAR_LIGAND_ID
3765	INN_ID
80061L1WGD	UNII
101	MMSL
2261	MMSL
4448	MMSL
4449	MMSL
6098	MMSL
d00140	MMSL
003415	NDDF
004987	NDDF
373541007	SNOMEDCT_US
83051006	SNOMEDCT_US
83532008	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8192	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8204	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0093-8305	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
Good Sense Heartburn Relief	HUMAN OTC DRUG LABEL	1	0113-0022	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0649	SOLUTION	300 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0649	SOLUTION	300 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1298	SOLUTION	400 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0121-1298	SOLUTION	400 mg	ORAL	ANDA	15 sections
cimetidineacid reducer	HUMAN OTC DRUG LABEL	1	0363-0022	TABLET, FILM COATED	200 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0053	TABLET, FILM COATED	200 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0317	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0372	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	0378-0541	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1282	TABLET	400 mg	ORAL	ANDA	15 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-626	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	10544-627	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-048	TABLET, FILM COATED	300 mg	ORAL	ANDA	17 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-265	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-372	TABLET, FILM COATED	800 mg	ORAL	ANDA	20 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-531	TABLET	300 mg	ORAL	ANDA	14 sections
CIMETIDINE	HUMAN PRESCRIPTION DRUG LABEL	1	21695-532	TABLET	400 mg	ORAL	ANDA	14 sections
Good Neighbor Pharmacy Heartburn Relief	HUMAN OTC DRUG LABEL	1	24385-111	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Acid Reducer	HUMAN OTC DRUG LABEL	1	30142-323	TABLET, FILM COATED	200 mg	ORAL	ANDA	16 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	33261-024	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-217	TABLET, FILM COATED	300 mg	ORAL	ANDA	20 sections
Cimetidine	HUMAN PRESCRIPTION DRUG LABEL	1	42291-218	TABLET, FILM COATED	400 mg	ORAL	ANDA	20 sections
Equate Cimetidine	HUMAN OTC DRUG LABEL	1	49035-820	TABLET, FILM COATED	200 mg	ORAL	ANDA	15 sections